ReviewCurrent neurology and neuroscience reports2022
Predictors of RBD progression and conversion to synucleinopathies.
Review in Current neurology and neuroscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum.Brain : a journal of neurology · 2026Article
- Decoding Prodromal Lewy Body Disease: Clinical Differences Between Isolated REM Sleep Behavior Disorder and Hyposmia With Dopamine Transporter Deficit.European journal of neurology · 2026Article
- Neuromelanin-sensitive MRI for identifying dopamine transporter imaging abnormality risk in idiopathic rapid eye movement sleep behavior disorder.Brain imaging and behavior · 2026Article
- Deep learning-based susceptibility map-weighted imaging analysis of dorsal nigral hyperintensity as a surrogate for dopamine transporter positron emission tomography in patients with idiopathic rapid eye movement sleep behavior disorder.Frontiers in neurology · 2026Article
- Differential Proteomic Landscape of Plasma Neuron-Derived Extracellular Vesicles in Parkinson's Disease with and without RBD: A Pilot Investigation.International journal of nanomedicine · 2026Article
- Case Report: non-monotonic longitudinal RSWA with tonic-phasic dissociation across serial attended video-polysomnography in isolated REM sleep behaviour disorder.Frontiers in sleep · 2026Article
- Cyclic Alternating Pattern and Sleep Microstructure in Parkinson's Disease: A Systematic Review and Meta-Analysis.Nature and science of sleep · 2026Review
- Susceptibility and diffusion MRI biomarkers predict development of Parkinsonism in iRBD.NPJ Parkinson's disease · 2025Article
- Sleep in neurodegenerative diseases: A focus on melatonin, melanin-concentrating hormone and orexin.Journal of neuroendocrinology · 2025Review
- Sleep Disturbances Across Dementias and Cognitive Decline: Study Protocol for a Systematic Review and Network Meta-Analysis of Polysomnographic Findings.Journal of clinical medicine · 2025Article
- The Future of Parasomnias.Journal of sleep research · 2025Review
- Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinson's disease · 2025Review
- Article
- Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians.Neurology and therapy · 2024Article
- Rapid eye movement sleep behavior disorder and its relation to Parkinson's disease: The potential of graph measures as brain biomarkers to identify the underlying physiopathology of the disorder.Brain and behavior · 2024Review
- Recent updates in autonomic research: orthostatic hypotension in prodromal synucleinopathy; longitudinal morbidity and mortality in orthostatic hypotension with and without supine hypertension; a cardiac vagal sensory system underlying reflex syncope.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2024Article
- Risk stratification for phenoconversion in patients with isolated REM sleep behavior disorder. A follow-up study from Turkey.Revista de neurologia · 2024Article
- Relationships Between Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease: Indication from Gut Microbiota Alterations.Aging and disease · 2024Article
- CardiacClinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023Review
- Circadian disruption and sleep disorders in neurodegeneration.Translational neurodegeneration · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewRapid eye movement (REM) sleep behaviour disorder (RBD) is considered the expression of the initial neurodegenerative process underlying synucleinopathies and constitutes the most important marker of their prodromal phase. This article reviews recent research from longitudinal research studies in isolated RBD (iRBD) aiming to describe the most promising progression biomarkers of iRBD and to delineate the current knowledge on the level of prediction of future outcome in iRBD patients at diagnosis. RECENT
findingsLongitudinal studies revealed the potential value of a variety of biomarkers, including clinical markers of motor, autonomic, cognitive, and olfactory symptoms, neurophysiological markers such as REM sleep without atonia and electroencephalography, genetic and epigenetic markers, cerebrospinal fluid and serum markers, and neuroimaging markers to track the progression and predict phenoconversion. To-date the most promising neuroimaging biomarker in iRBD to aid the prediction of phenoconversion is striatal presynaptic striatal dopaminergic dysfunction. There is a variety of potential biomarkers for monitoring disease progression and predicting iRBD conversion into synucleinopathies. A combined multimodal biomarker model could offer a more sensitive and specific tool. Further longitudinal studies are warranted to iRBD as a high-risk population for early neuroprotective interventions and disease-modifying therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.